#NephJC Transcript
Healthcare social media transcript of the #NephJC hashtag.
– ().
See #NephJC Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Nephrology Journal Club @NephJC T-1 hour to the European #NephJC on the CREDENCE trial—Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. Hoping some of the authors can join us (again!) [REDACTED USER] [REDACTED USER] Rajiv Agarwal of @IUKidney @gbakris @DavidCWheeler2 @adeeralevin https://t.co/hkS4PEp9mh |
 | Laura Slattery @Slatts_1 RT @NephJC: T-1 hour to the European #NephJC on the CREDENCE trial—Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. Hop… |
 | Kamel Hatahet @kamel_hatahet RT @aishaikh: The #CREDENCE Trial was discussed @NephJC last night. We were fortunate to have the lead author of the paper [REDACTED USER] j… |
| Nephrology Journal Club @NephJC T1 Pre-specified guidance proposed recommendation of possible early cessation if evidence of benefit was observed for the primary outcome(p<0.01) and the composite of ESKD or death from renal or CV causes(p<0.025)considering the overall balance of risks and benefits. #NephJC https://t.co/FJYruMMDQJ |
 | Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel nearly time #nephjc |
| Nephrology Journal Club @NephJC Good evening everyone! It’s 08:00PM which means it is time for the European #NephJC. Welcome to tonight’s discussion. |
 | manuel macia heras @mmacia25 RT @NephJC: T-1 hour to the European #NephJC on the CREDENCE trial—Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. Hop… |
| Nephrology Journal Club @NephJC I’m Ted Fitzgerald @Ted_FitzG and I’ll be your co-host with Laura Slattery @ Slatts_1 tonight as we discuss this paper. We’re both adult Nephrology trainee working in University Hospital Waterford, Ireland #NSMCunite #NephJC. https://t.co/pe0dfteC9T |
| Nephrology Journal Club @NephJC Please introduce yourself (even if you’re just lurking and following along) and declare any Conflicts of Interests. Don’t forget to use the hashtag #NephJC. And here’s the quick guide on “How to #NephJC. https://t.co/LPybW9CFtY |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel Rab in the Sunny Highlands of Scotland@nhshrenal no coi #nephjc |
 | Colin Geddes @geddescc #NephJC colin Geddes Glasgow. No COI |
| Nephrology Journal Club @NephJC The paper we will be discussing is “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy” by Perkovic et al published in NEJM this month. It has caused a considerable stir in the #NephTwitter community since its release which makes it an excellent #NephJC choice. |
| Nephrology Journal Club @NephJC Happy 5th Birthday to #NephJC! |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome Alex #NephJC |
| Laura Slattery @Slatts_1 @rabpeel Welcome @rabpeel #NephJC |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome Alex #NephJC |
| Nephrology Journal Club @NephJC Didn’t have time to sift through the entire paper and supplementary material? Check out the excellent summary by [REDACTED USER] #NephJC https://t.co/4MdXRrf78t |
| Laura Slattery @Slatts_1 @Ashidotic Welcome Neil, we're likewise excited! #NephJC |
| Laura Slattery @Slatts_1 @logiebear111 @NephJC Welcome Ian #NephJC |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome [REDACTED USER] #NephJC |
| Nephrology Journal Club @NephJC Check out these brilliant visual abstracts by @MarioFunesMD created for #NephJC and [REDACTED USER] created for @georgeinstitute https://t.co/F5mLyfTdDC |
| Nephrology Journal Club @NephJC Without further ado…let us move onto T0 and the background #NephJC |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome [REDACTED USER] #NephJC |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome Francesco! #NephJC |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome Sarah! #NephJC |
| Nephrology Journal Club @NephJC T0: To say that diabetes and its complications are an epidemic would be an understatement. Given that 30-40% of people with diabetes ultimately develop diabetic kidney disease, renal physicians are likely to be treating these individuals with ever increasing frequency #NephJC |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome Edoardo! #NephJC |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome Hugo, great birthday party! #NephJC |
| Laura Slattery @Slatts_1 @unicipa Welcome Zoran #NephJC |
| Nephrology Journal Club @NephJC T0: Unsurprisingly, this has resulted in a dearth of clinical trials investigating pharmacotherapies to halt or slow the progression of diabetic kidney disease. See the salient trials summarised excellently by [REDACTED USER] #NephJC https://t.co/aZKzTnNOKg |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome Mohamed! #nephjc |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome John #NephJC |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome Sinead! #NephJC |
| Nephrology Journal Club @NephJC T0: RAS blockade has remained the cornerstone of treatment to delay the progression of diabetic nephropathy. However, despite maximal RAS blockade, proteinuria does not completely regress and a significant proportion of patients progress to kidney failure. #NephJC |
| Nephrology Journal Club @NephJC [REDACTED USER] Welcome, Dr Holian #NephJC |
| Laura Slattery @Slatts_1 @toates_19 Welcome Tom! #NephJC |
| Laura Slattery @Slatts_1 [REDACTED USER] Welcome [REDACTED USER] #NephJC |
| Laura Slattery @Slatts_1 @geddescc Welcome @geddescc #NephJC |
| Nephrology Journal Club @NephJC T0: While there have been many new hypoglycaemic agents introduced in the last 2 decades, few of them have shown effect in altering disease progression. #NephJC |
| Nephrology Journal Club @NephJC T0: Linagliptin was renoprotective in animal models, this has not been replicated in human studies. CARMELINA did not demonstrate evidence of renoprotection. GLP-1 analogues have shown a modest effect on albuminuria, but no effect on GFR or tangible clinical outcomes #NephJC |
| @conorjudge Conor, Irish nephrology trainee, no COI. #nephjc | |
| Nephrology Journal Club @NephJC T0: SGLT2 inhibitors have increasingly drawn attention over the last decade. See this excellent AJKD blog from 2018 by Anna Burgner for an explanation of their mechanism of action #NephJC https://t.co/vYAJm8ozxF |
| Nephrology Journal Club @NephJC T0: In the EMPA-REG trial, use of empagliflozin decreased risk of doubling of creatinine (44%) and ESRD (55%) without any difference in albuminuria. We covered the renal results on #NephJC here. https://t.co/n7hAxa6WEf |
| Laura Slattery @Slatts_1 @toates_19 @VickiSandys1 Welcome Vicki! #NephJC |
| Nephrology Journal Club @NephJC T0: In CANVAS, canagliflozin reduced the risk of sustained and adjudicated major kidney outcomes. On the basis of the pre-specified hypothesis testing sequence, the renal outcomes were not viewed as statistically significant. #NephJC https://t.co/9NYPdzNoV7 |
| Nephrology Journal Club @NephJC T0: They did show a possible benefit of canagliflozin with respect to the progression of albuminuria (HR 0.73) and the composite outcome of a sustained 40% reduction in the eGFR, the need for RRT, or death from renal causes (HR 0.60). #NephJC https://t.co/4J1MT3ZVFv |
| Nephrology Journal Club @NephJC T0 See the below table summary of EMPA-REG, CANVAS and DECLARE #NephJC https://t.co/Qcap9l5b1b |
| Nephrology Journal Club @NephJC T0 One of the significant concerns has been the signal of higher amputations reported in CANVAS - and then reinforced by observational data from elsewhere. #NephJC https://t.co/XbSjFVc8aW |
| Colin Geddes @geddescc @toates_19 #nephjc based on trials I think purist would go for captopril for Type 1 and Irbesartan for type 2 but I suspect not much in it? Personally use ramipril first line for both types but if they are on another RAASi don’t change it. If need ARB then irbesartan or losartan |
| Nephrology Journal Club @NephJC T0 CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) was designed to assess the effects of canagliflozin on primarily the renal outcomes in patients with established nephropathy. #NephJC |
| Laura Slattery @Slatts_1 @werner02 Welcome @werner02 #NephJC |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel [REDACTED USER] we'll be telling our grand children of the time NephJC did Credence! #nephjc |
 | Bernadette @BouncyB101 RT @aishaikh: Q3: Why was only 5% of the CREDENCE trial population black? VP: Fair point. We worked really hard to recruit them but it was… |
| Laura Slattery @Slatts_1 [REDACTED USER] [REDACTED USER] Welcome [REDACTED USER], definitely, one not to miss! #NephJC |
| Nephrology Journal Club @NephJC T0: Of note, CREDENCE was initiated in 2014, before the results of EMPA-REG came out. Another important point to note was that previous trials tended to enrol patients with preserved GFR due to a theory that efficacy of these agents decreased with decreasing GFR #NephJC |
| Colin Geddes @geddescc [REDACTED USER] @NephJC RAASi pretty effective at slowing it down though #nephjc |
| Nephrology Journal Club @NephJC T0: Have you much experience with using these agents in your clinical practice? If so, do you find them beneficial? Any experience with adverse events? #NephJC |
 | Sally Johnson @docsallyj @logiebear111 @toates_19 I’m joining, better late than never. Paed nephrologist in Newcastle. No COI #nephjc |
| Laura Slattery @Slatts_1 [REDACTED USER] @NephJC Welcome Tomas! #NephJC |
| Nephrology Journal Club @NephJC T0: See the poll below #NephJC https://t.co/7xH1NUMCjf |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel @geddescc @toates_19 Losartan good if urate raised! |
| Nephrology Journal Club @NephJC T1: This was a randomised, double-blind, placebo-controlled trial conducted at 690 sites in 34 countries across North America, Latin America, South Africa and Asia Pacific. #NephJC https://t.co/SYT3DIiO5S |
| Colin Geddes @geddescc @rabpeel @toates_19 #nephjc over-rated I reckon. Not to say I haven’t tried it! |
| Nephrology Journal Club @NephJC T1 Because the trial was designed to study the impact of Canagliflozin on the progression of CKD, the intent was that at least 60% of the patient population have CKD stage 3 (rather than stage 2), with an eGFR of 30-60 ml/min/1.73m2. #NephJC https://t.co/0OPh2afP5l |
 | Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 #NephJC @gratefull080504 : COI: @OtsukaUS Gilead, Bayer, Protalix, Retrophin, CareDx Hansa |
| Nephrology Journal Club @NephJC T1 Patients who met the eligibility criteria were enrolled in a 2-week, single-blind placebo-run in period. Those who failed to take ≥80% of the scheduled run-in treatment were deemed ineligible. #NephJC |
| Nephrology Journal Club @NephJC [REDACTED USER] And Europe indeed #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @NephJC Screened 12,000 patients #nephJC |
| Nephrology Journal Club @NephJC T1 Eligible patients were randomized (1:1) to receive either Canagliflozin (100mg orally once daily) or matching placebo. Randomisation was stratified according to the category of estimated GFR at the time of screening #NephJC https://t.co/5ECnuUP5dR |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel T0 the lower eGFRs is the best bit about this trial set up for me #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 [REDACTED USER] @NephJC ?????? #nephJC |
| Nephrology Journal Club @NephJC T1 Glycemic control was reinforced with diet, exercise counselling and also as per the discretion of the responsible physician. Patients were followed up at 3, 13 and 26 weeks and then alternated between telephone calls and out-patient visits every 13 weeks. #NephJC https://t.co/ttwagcFzZM |
| Nephrology Journal Club @NephJC RT @rabpeel: T0 the lower eGFRs is the best bit about this trial set up for me #nephjc |
| Nephrology Journal Club @NephJC T1 Pre-specified guidance recommended early cessation if benefit was observed for the primary outcome (p<0.01) and the composite of ESKD or death from renal or cardiovascular causes (p<0.025), with consideration of the overall balance of risks and benefits. #NephJC https://t.co/AsjyO9VQun |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @rabpeel In section B the renal benefit was the most striking positive aspect of the trial #nephJC |
| Nephrology Journal Club @NephJC Onto T2 and the results #NephJC |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel @gratefull080504 @rabpeel but the lower eGFRs were not in the previous studies so we never found out- so set up crucial #nephjc |
| Nephrology Journal Club @NephJC T2: In terms of baseline demographics, all patients had diabetic nephropathy with duration of diabetes of mean 15.5 years. About two-thirds were on insulin and over half on metformin. #NephJC https://t.co/mUeuALgxmE |
| Nephrology Journal Club @NephJC T2 Despite the 30 ml/min GFR floor, about 170 participants with GFR 15-30 were included. 10% had nephrotic range proteinuria and another three-quarters were non-nephrotic, but had macroalbuminuria. #NephJC https://t.co/gdoSveebzg |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 [REDACTED USER] @NephJC Yes it is It least patients will receive good patient care #nephJC |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel @toates_19 I prescribe and re prescribe more MF than de-prescribe! #nephjc |
| Nephrology Journal Club @NephJC T2 Anti-hyperglycaemic therapy summarised below #NephJC https://t.co/DEZl6YC2s7 |
| Laura Slattery @Slatts_1 [REDACTED USER] @NephJC Makes a solid case for the importance of MDT, community and hospital input #NephJC |
| Nephrology Journal Club @NephJC T2 By the time all events were adjudicated and recorded ~ 500 primary outcome events had occurred. #NephJC |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel @toates_19 thank you #nephjc |
| Nephrology Journal Club @NephJC T2:There was a 30% relative risk reduction in the primary composite endpoint of ESKD, doubling of sCr and renal or CV death; line segments diverged as early as 1 yr after randomisation (event rate 43.2 vs 61.2/1000 patient-years respectively in canagliflozin vs placebo)#NephJC |
| Nephrology Journal Club @NephJC [REDACTED USER] [REDACTED USER] @toates_19 Happy to get an endocrinologist's view! #NephJC |
| Nephrology Journal Club @NephJC T2 The relative risks of ESKD, doubling of serum creatinine and death due to cardiovascular cause were reduced by 32%, 40% and 22% respectively. #NephJC https://t.co/yabRTl64PI |
| Nephrology Journal Club @NephJC T2 With respect to relative risk reduction in the primary outcomes, the effect was consistent across all subgroups on subgroup analysis #NephJC https://t.co/vlyla3geIV |
| Nephrology Journal Club @NephJC T2: There was no significant difference in the risk of CV death therefore subsequently listed outcomes in the hierarchy were not formally evaluated #NephJC |
| Nephrology Journal Club @NephJC T2: With secondary outcomes, patients in the canagliflozin arm had a lower risk for most secondary outcomes (statistically significant for outcomes 1st-4th). #NephJC https://t.co/CgaXOGXIyc |
| Nephrology Journal Club @NephJC [REDACTED USER] Doesn't specify class but Table S1 in Supplements says 1026 patients in the Cana grp were on diuretic and 1031 in the placebo grp were on diuretic at time of trial entry (~46% of each pop) #NephJC |
 | Mana @manasigh RT @NephJC: T1 Glycemic control was reinforced with diet, exercise counselling and also as per the discretion of the responsible physician.… |
| Nephrology Journal Club @NephJC T2: The degree of albuminuria was 31% lower compared with placebo. This difference appears almost immediately, suggesting an early hemodynamic mechanism probably mediated by reduced intraglomerular pressure. #NephJC https://t.co/XJqzWaQkLw |
| Nephrology Journal Club @NephJC T2: This may be supported by early GFR decline seen in the first few weeks of initiation of Canagliflozin; thereafter the decline in eGFR remains gentler for Canagliflozin, for a difference of 2.74 ml/min/1.73m2. #NephJC https://t.co/qavWY02qS7 |
| Colin Geddes @geddescc [REDACTED USER] @logiebear111 @toates_19 #nephjc but this paper was at initiation of type 2 DM. Presumably prevalence less for patients median 15 years from diagnosis? |
| Nephrology Journal Club @NephJC T2: The mean difference in systolic and diastolic BP were 3.30 and 0.95 mmHg, lower in the Canagliflozin arm. Again, this is too small a difference to result in such a large nephroprotective effect. #NephJC |
| Nephrology Journal Club @NephJC T2: Baseline mean HbA1C across both the groups was 8.3%. While the mean levels were lower in Canagliflozin arm the difference was marginal (mean being 0.25% and end of study difference being just 0.11%). #NephJC https://t.co/QUf722mw8V |
| Nephrology Journal Club @NephJC T2: In terms of adverse events, lower limb amputation and fracture rates were similar across both groups (in stark contrast with CANVAS). #NephJC https://t.co/NJmChSnTA8 |
| Nephrology Journal Club @NephJC T2: A protocol amendment asked investigators to examine patients’ feet at each trial visit and temporarily interrupt the assigned treatment in patients with any active condition that might lead to amputation. #NephJC |
| Nephrology Journal Club @NephJC [REDACTED USER] Supplementary material states maximum approved labelled dose for DN/HTN unless side effects limit use of maximum dose. Investigators had to document why higher dose wasn't used. Both groups had to be established for minimum 4 weeks on this dose. >99% in both on RAAS #NephJC |
| Nephrology Journal Club @NephJC T2: Ketoacidosis was detected with greater frequency in the canagliflozin arm than the placebo. #NephJC https://t.co/3pPhofN9uB |
| Nephrology Journal Club @NephJC T2: Overall, urinary tract infections occurred at similar frequencies in both the arms (48 vs 45 episodes per 1000 patient-years). However, genital mycotic infections occurred more commonly in patients receiving canagliflozin. #NephJC https://t.co/Q0PsW9KvTf |
 | Ayanfe Obilana @AyanfeObilana Ayanfe, Irish Nephrology SpR, late to the CREDENCE party and lurking, looking forward to learning. No COI #nephjc |
| Nephrology Journal Club @NephJC T2: Any thoughts on the results? #NephJC |
| Nephrology Journal Club @NephJC Onto T3 and the discussion #NephJC |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel T2 it is a shame they stopped it early all the same! #nephjc |
| Nephrology Journal Club @NephJC T3: The authors conclude that in patients with T2DM and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years #NephJC |
| Nephrology Journal Club @NephJC First author in the house! Welcome [REDACTED USER] #NephJC |
| Nephrology Journal Club @NephJC T3: Is it time to get excited about these medications? Will they be part of our prescribing armamentarium? #NephJC |
| Nephrology Journal Club @NephJC T3: Strengths of the study include 1. The primacy given to renal outcomes 2. Benefit over and above RAS blockade was examined 3. Large clinical trial population #NephJC |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel @logiebear111 @NephJC T3 Fire and forget, like the statins? #nephjc |
| Nephrology Journal Club @NephJC T3: Limitations include 1. Premature termination of the trial limited the power for at least some secondary outcomes 2. As with most trials, those with advanced kidney disease (GFR < 30) were excluded from the study, though a few patients with GFR 15-30 did make it in. #NephJC |
| Nephrology Journal Club @NephJC T3: This raises a question of generalisability and to consider at what GFR (if any) would one not use or stop an SGLT2i. #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 I hope so especially that upstream interventions can be initiated + slow down the progression of #KidneyDisease When I was diagnosed with #adokd I would have loved to have an option to slow down profession of #adpkd What is the downside? I don’t see one #nephJC |
| Nephrology Journal Club @NephJC T3 Are you reassured by the safety data, particularly that relating to amputations? #NephJC |
| Nephrology Journal Club @NephJC [REDACTED USER] Patients with renal transplant (and those on immunosuppressive therapy) were excluded from the trial #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @logiebear111 @NephJC Nephrologists! #nephJC |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel @NephJC well how long to know when to stop ACE /ARBs just keep it going? #nephjc |
| Nephrology Journal Club @NephJC T3: Any other thoughts on the strengths and limitations? #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @NephJC In addition the number of patients , 645 sites, global study etc #nephJC |
| Nephrology Journal Club @NephJC T3 How do you envisage these results will change your clinical practice? #NephJC |
| Sally Johnson @docsallyj @logiebear111 I'm learning loads tonight. First irbesartan is an anagram of Serbian art and now how to prevent athletes foot. Thank you #nephjc |
| Nephrology Journal Club @NephJC Final few minutes: what are your take-home points? #NephJC |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel T3 I will be more confident to ignore the eGFR<60 rules with SLGT2i #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Can someone tell me why you would not be excited? In most situations #dialysis robs you of your life + dignity #nephJC |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel [REDACTED USER] @NephJC I can't imagine for long though #nephjc |
| Nephrology Journal Club @NephJC Thanks for joining us tonight and for contributing to the discussion. #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 This is no different than current #diabetic #kidneydisease trials #nephJC |
| Colin Geddes @geddescc @logiebear111 @NephJC #nephjc seems strange that nephrologists won’t be the experts at prescribing a drug that acts only on the kidney. But agree at present appropriate most of the prescribing in UK done in primary care |
| Nephrology Journal Club @NephJC Thanks again to [REDACTED USER] for the summary and @MarioFunesMD for the VA. #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 [REDACTED USER] [REDACTED USER] @Ashidotic Thank you! An infection can easily be managed compared to #dialysis #NephJC |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel and don't forget the fabulous Credence sweet water revival! #nephjc |
| Nephrology Journal Club @NephJC Please also sign up for our weekly newsletter at https://t.co/5aumn8ImwF #NephJC Looking for some #NephJC swag? Order it here https://t.co/eTUrZYjJeY |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 I think there will be a place with #kidneytransplant recipients We can have kidneys last longer #NephJC |
| Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel Thank you and goodnight #nephjc |
 | J. Brian Byrd Lab @thebyrdlab #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @geddescc @logiebear111 @NephJC Good grief! If #nephrologists want a future profession you take the lead + change the way patient care is practiced Leaders need to appear #nephJC |
| Nephrology Journal Club @NephJC Until next time…thank you and good night! #NephJC |
| J. Brian Byrd Lab @thebyrdlab @toates_19 [REDACTED USER] What I see in the list: Certain olmesartan, candesartan, valsartan & telmisartan products are on the list of 40 US-marketed ARB products FDA knows to be impurity-free Other products containing these ARBs & all products containing other ARBs are still undergoing testing #NephJC |
| Colin Geddes @geddescc [REDACTED USER] [REDACTED USER] #nephjc beneficial in both is my bet |
| @AravindCheruku1 [REDACTED USER] [REDACTED USER] | |
| J. Brian Byrd Lab @thebyrdlab @toates_19 [REDACTED USER] What I see in the list: Certain olmesartan, candesartan, valsartan & telmisartan products are on the list of 40 US-marketed ARB products FDA knows to be impurity-free Other products containing these ARBs & all products containing other ARBs are still being evaluated #NephJC |
 | Steven Coca @scoca1 @aishaikh with another DOMINANT neph twitter performance!! En fuego!! 🔥🔥🔥 🎉🎉🙌🏼💪🏼💪🏼💪🏼 |
 | Max Benjamin MD @mmaxbenji @aishaikh [REDACTED USER] @NephJC [REDACTED USER] @kidney_boy That was such a fluid and instructive interview. Twitter is such a good medium for this. To be attempted for further major studies discussions. |
 | Matthew Sparks, MD @Nephro_Sparks The #CREDENCE numbers: 2,554 Tweets. 482 Participants. 7,721,839 Impressions. April 23rd 2019. More #NephJC 📊 here https://t.co/Yof2L1ytEj via @symplur |
 | madree @madrees007 RT @NephJC: T2: The degree of albuminuria was 31% lower compared with placebo. This difference appears almost immediately, suggesting an ea… |
#NephJC content from Twitter.